Purchase this article with an account.
Wataru Yamada, Akira Sawada, Tetsuya Yamamoto; A randomized crossover study comparing efficacy of fixed-combination travoprost and timolol, and bimatoprost in open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5701.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the intraocular pressure (IOP) lowering efficacy of fixed-combination travoprost and timolol, and bimatoprost 0.03% in eyes with open-angle glaucoma (OAG).
This was a prospective, open-label, randomized, and crossover clinical trial of 54 OAG patients who were receiving treatment either fixed-combination travoprost and timolol or bimatoprost each given once every evening for 8 weeks, after which they were crossed over to the other medication for another 8 weeks. Visits were at baseline, weeks 2, 4, 8, 10, 12, 16. At untreated baseline and at the end of each treatment period the IOP was measured at 10 AM, noon, and 4 PM in a sitting position with Goldmann applanation tonometry. One eye was randomly chosen for further analyses. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 8 weeks of treatment compared with baseline.
Fifty-four OAG patients participated, and two subjects were discontinued this study. The mean baseline IOP was 13.3 ± 1.5 mmHg. Bimatoprost reduced IOP by 2.0 ± 1.5 mm Hg (14.5 ± 10.9 %) and fixed-combination travoprost and timolol by 2.2 ± 1.4 mm Hg (16.2 ± 9.7 %) from the baseline. There were no significant differences in IOP reduction between the two groups (P=0.147). Ocular hyperemia was the most frequently developed adverse event, which was seen in 24 patients (46.2%) treated with bimatoprost as compared with 23 patients (44.2%) treated with fixed-combination travoprost and timolol (P=0.904), followed by hypertrichosis and hyperpigmentation of the eye lid.
Bimatoprost was similarly effective in reducing IOP compared with fixed-combination travoprost and timolol in glaucoma patients with relatively low IOP.
This PDF is available to Subscribers Only